Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Web-based Genetic Research on Parkinson's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by 23andMe, Inc.
Sponsor:
Collaborators:
Michael J. Fox Foundation for Parkinson's Research
The Parkinson's Institute
Information provided by (Responsible Party):
23andMe, Inc.
ClinicalTrials.gov Identifier:
NCT01351467
First received: May 9, 2011
Last updated: August 14, 2015
Last verified: August 2015
  Purpose
The purpose of this study is to examine how genes and environment affect risk for Parkinson's disease.

Condition
Parkinson's Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives

Resource links provided by NLM:


Further study details as provided by 23andMe, Inc.:

Primary Outcome Measures:
  • Saliva DNA test and online surveys with questions about Parkinson's disease experience, symptoms and response to treatment [ Time Frame: Intermittent surveys every 6 months for up to 24 months ] [ Designated as safety issue: No ]
    We want to learn how genes and environment could play role in Parkinson's disease risk and progression


Biospecimen Retention:   Samples With DNA
Saliva samples are collected for DNA analysis

Estimated Enrollment: 25000
Study Start Date: April 2009
Estimated Study Completion Date: January 2025
Estimated Primary Completion Date: January 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts
Parkinson's disease patients
People diagnosed with Parkinson's disease by a physician

Detailed Description:
23andMe has created a web-based Parkinson's research initiative to understand the genetic associations found between Parkinson's patients' DNA and their disease. To learn more, visit: https://www.23andme.com/pd/. You can participate in this research initiative without leaving home. If you are eligible to participate, we will send you an in-home 23andMe DNA kit at no cost. We will ask you short online surveys (15-20) about your Parkinson's journey, symptoms, and response to treatment. Enrollment is on-going and open to individuals who have been diagnosed with Parkinson's disease and are residents of the U.S. Participants receive access to ancestry information and uninterpreted genetic data. Participants will also receive regular updates on our research efforts and findings.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Community Sample
Criteria

Inclusion Criteria:

  • diagnosis of Parkinson's disease by a physician

Exclusion Criteria:

  • diagnoses other than Parkinson's, including:
  • progressive supranuclear palsy (PSP)
  • multiple system atrophy (MSA)
  • Shy-Drager syndrome
  • spinal cerebella ataxia (SCA)
  • atypical parkinsonism
  • parkinsonism due to medications, drug-induced parkinsonism
  • vascular parkinsonism
  • frontotemporal dementia with parkinsonism
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01351467

Contacts
Contact: Paul Cannon, Ph.D. 6509386300 pd-help@23andme.com

Locations
United States, California
Www.23Andme.Com/Pd Recruiting
Mountain View, California, United States, 94043
Contact: Paul Cannon, Ph.D.    650-938-6300    pd-help@23andme.com   
Sponsors and Collaborators
23andMe, Inc.
Michael J. Fox Foundation for Parkinson's Research
The Parkinson's Institute
  More Information

Additional Information:
Publications:
Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP; 23andMe Genetic Epidemiology of Parkinson's Disease Consortium.; International Parkinson's Disease Genomics Consortium.; Parkinson's Disease GWAS Consortium.; Wellcome Trust Case Control Consortium 2)., Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JP, Bertram L. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet. 2012;8(3):e1002548. doi: 10.1371/journal.pgen.1002548.
Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC).; Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI).; 23andMe.; GenePD.; NeuroGenetics Research Consortium (NGRC).; Hussman Institute of Human Genomics (HIHG).; Ashkenazi Jewish Dataset Investigator.; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE).; North American Brain Expression Consortium (NABEC).; United Kingdom Brain Expression Consortium (UKBEC).; Greek Parkinson's Disease Consortium.; Alzheimer Genetic Analysis Group., Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014 Sep;46(9):989-93. doi: 10.1038/ng.3043.

Responsible Party: 23andMe, Inc.
ClinicalTrials.gov Identifier: NCT01351467     History of Changes
Other Study ID Numbers: 23andMe_PD001 
Study First Received: May 9, 2011
Last Updated: August 14, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by 23andMe, Inc.:
Parkinson's
genetic
online
GWAS
genome wide association

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on December 02, 2016